Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray

Molecular Carcinogenesis

Volumn 47, Issue 9, 2008, Pages 678-685

  Harris, Loleta D ^a   De La Cerda, Jorge ^a   Tuziak, Tomasz ^a   Rosen, Daniel ^a   Xiao, Lianchun ^a   Shen, Yu ^a   Sabichi, Anita L ^a   Czerniak, Bogdan ^a   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder neoplasms; Tissue microarray analysis; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; CONNEXIN 26; L PLASTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN DRG 1; PROTEIN KINASE B; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA;

BIOLOGICAL MARKERS; CARCINOMA, TRANSITIONAL CELL; CONNEXINS; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 50249187810     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20420     Document Type: Article

References (32)

1. Bandyopadhyay S, Pai SK, Hirota S, et al. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res 2004;64:7655-7660.
2. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803.
3. Lapillonne A, Coue O, Friederich E, et al. Expression patterns of L-plastin isoform in normal and carcinomatous breast tissues. Anticancer Res 2000;20:3177-3182.
4. Otsuka M, Kato M, Yoshikawa T, et al. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem Biophys Res Commun 2001;289:876-881.
5. Sheen IS, Jeng KS, Wang PC, et al. Are gap junction gene connexins 26,32 and 43 of prognostic values in hepatocellular carcinoma? A prospective study. World J Gastroenterol 2004;10:2785-2790.
6. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lunq cancer confers poor prognosis. Lung Cancer 2006;51:181-191.
7. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: A tissue-array-based analysis. Mod Pathol 2006;19:238-245.
8. Slipicevic A, Holm R, Nguyen MT, Bohler PJ, Davidson B, Florenes VA. Expression of activated Akt and PTEN in malignant melanomas: Relationship with clinical outcome. Am J Clin Pathol 2005;124:528-536.
9. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000;19:5406-5412.
10. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10:4874-4884.
11. Wu X, Obata T, Khan Q, Highshaw RA, de Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004;93:143-150.
12. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 2003;10:1636-1642.
13. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-2963.
14. Ulrix W, Swinnen JV, Heyns W, Verhoeven G. The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells. FEBS Lett 1999;455:23-26.
15. Oyamada Y, Oyamada M, Fusco A, Yamasaki H. Aberrant expression, function and localization of connexins in human esophageal carcinoma cell lines with different degrees of tumorigenicity. J Cancer Res Clin Oncol 1994;120:445-453.
16. Terzaghi-Howe M, Chang GW, Popp D. Emergence of undifferentiated rat tracheal cell carcinomas, but not squamous cell carcinomas, is associated with a loss of expression of E-cadherin and of gap junction communication. Carcinogenesis 1997;18:2043-2050.
17. Gee JT, Tanaka M, Grossman HB. Connexin 26 is abnormally expressed in bladder cancer. J Urol 2003;169: 1135-1137.
18. Tanaka M, Grossman HB. Connexin 26 gene therapy of human bladder cancer: Induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 2001;12:2225-2236.
19. Lin CS, Lau A, Yeh CC, Chang CH, Lue TF. Upregulation of L-plastin gene by testosterone in breast and prostate cancer cells: Identification of three cooperative androgen receptor-binding sequences. DNA Cell Biol 2000;19:1-7.
20. Zheng J, Rudra-Ganguly N, Miller GJ, Moffatt KA, Cote RJ, Roy-Burman P. Steroid hormone induction and expression patterns of L-plastin in normal and carcinomatous prostate tissues. Am J Pathol 1997;150:2009-2018.
21. Kim JH, Tuziak T, Hu L, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 2005;85:532-549.
22. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-277.
23. Koksal IT, Yasar D, Dirice E, et al. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int 2005;75:102-106.
24. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 2005;65:8096-8100.
25. Mo L, Zheng X, Huang HY, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007;117:314-325.
26. Li GY, Lin HH, Tu ZJ, Kiang DT. Gap junction Cx26 gene modulation by phorbol esters in benign and malignant human mammary cells. Gene 1998;209:139-147.
27. Muramatsu A, Iwai M, Morikawa T, et al. Influence of transfection with connexin 26 gene on malignant potential of human hepatoma cells. Carcinogenesis 2002;23:351-358.
28. Tanaka M, Grossman HB. Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 2004;11:537-541.
29. Ito A, Koma Y, Uchino K, et al. Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: Significant correlation with poor prognosis. Cancer Lett 2006;234:239-248.
30. Ito A, Watabe K, Koma Y, Kitamura Y. An attempt to isolate genes responsible for spontaneous and experimental metastasis in the mouse model. Histol Histopathol 2002;17:951-959.
31. Kanczuga-Koda L, Sulkowski S, Koda M, Sulkowska M. Alterations in connexin26 expression during colorectal carcinogenesis. Oncology 2005;68:217-222.
32. Park T, Chen ZP, Leavitt J. Activation of the leukocyte plastin gene occurs in most human cancer cells. Cancer Res 1994;54:1775-1781.